Trials / Completed
CompletedNCT02145663
Helsinki Ultra-acute Stroke Biomarker Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,046 (actual)
- Sponsor
- Helsinki University Central Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to establish diagnostic and predictive biomarkers for patients with suspected acute stroke, that are transported by EMS as candidates for thrombolytic treatment. The study focuses on the ultra acute phase, \<4.5 hours from symptom onset, including the prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2 peptide) and a discovery phase for novel markers. Patient outcome will be evaluated at 3 month using the modified Rankin Scale (mRS).
Conditions
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2016-02-01
- First posted
- 2014-05-23
- Last updated
- 2016-04-01
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT02145663. Inclusion in this directory is not an endorsement.